Full Press Release Details
The first and only All-in-one subscription platform offering all of your PR Distribution and Media Outreach Tools in one single solution. Monthly & Annual Subscriptions.
Find & create journalist lists with the most up to date database in the industry.
Personalize and customize your pitch for maximum engagement.
Discover your brand, industry, and competitor mentions.
Now you can track every mention, every conversation, and every shift in sentiment — all from the platform you're already using.
Turn your PR data into actionable intelligence with comprehensive reporting and analytics on every campaign.
Catch issues before our editors do. ACCESS Verified gives you a real-time first pass on your press release so you can submit with confidence — every time.
The first and only All-in-one subscription platform that offers you the ability to manage all of your IR communications needs from a single source. Explore our IR subscriptions
Explore how you can upgrade your IR Site today.
Ensure your IR Site is accessible for your entire audience.
Experience seamless calls with our dedicated team of domestic operators.
Easily send your releases out with quick turnarounds and no extra fees.
Host your day knowing you've got the most experienced webcast team in the industry.
Provide a secure and confidential reporting channel to protect your organization and employees.
Streamline your PR & IR needs with one platform.
Easily schedule and manage your investor meetings with our comprehensive and easy to use software.
Our PR and IR tools are designed to meet all necessary regulatory requirements, giving you the confidence to communicate effectively and compliantly. Streamline your communications needs today with our one-stop shop offering.
Whether a startup or established brand, we deliver the support, targeted distribution, media outreach, and flexible pricing & payment options needed to amplify your story with confidence.
We simplify the process of delivering success for both you and your clients. We understand the importance of getting it right, equipping you with seamless billing, flexible plans and payment structures, and clear reporting and analytics to ensure every campaign runs smoothly and achieves measurable results.
We understand the need to manage high volume of press release distribution efficiently. That's why we offer a dedicated API designed specifically for our legal customers, delivering a streamlined, simple process that ensures value and ease at every step.
We understand the importance of cost efficiency for high-volume partners, which is why we offer bulk discounts tailored to meet your needs while maximizing value.
Designed for brands that need help consistently fueling their content strategy and calendar with optimized press releases, blogs, and more…
Tailored for brands with a solid content strategy seeking support for effectively reaching and engaging the media.
Made for brands that need more comprehensive support building and managing their content strategy, media outreach and engagement plan.
Personalized support to optimize your platform, including tailored journalist list creation, pitch guidance, and monitoring setup.
Continual support and management including ongoing list creation, pitch creation and modifications, monitoring adjustments, and additional reporting and analytics review.
Press Release creation and optimization for SEO and audience engagement
Back to the Newsroom CNS Pharmaceuticals Reports Third Quarter 2026 Financial Results and Highlights Progress in Establishing Transformative Therapeutic Pipeline Monday, 16 November 2026 07:30 AM
Company has been exploring multiple acquisition and licensing opportunities, with the goal of securing first transaction by year-end
$17.2 million cash position provides financial strength to support strategic execution and planned operations
HOUSTON, TX / ACCESS Newswire / November 16, 2026 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2026 and provided an update on its corporate strategy.
CNS Pharmaceuticals continues to make meaningful progress in executing its pipeline expansion strategy, advancing discussions with potential counterparties regarding the acquisition or licensing of innovative therapeutic assets in neurology, oncology or rare disease. The Company remains focused on completing its first pipeline-building transaction by year-end 2026, an important anticipated milestone in its strategic transformation.
"We are approaching an important inflection point in the evolution of CNS Pharmaceuticals," said Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals. "Our efforts to identify and evaluate compelling therapeutic opportunities have progressed into advanced discussions with potential counterparties, bringing us closer to establishing the foundation of our next-generation pipeline. We are encouraged by the quality of the opportunities under consideration and remain intensely focused on translating these discussions into a meaningful transaction. Our objective is clear: secure a differentiated asset with the potential to drive clinical development, establish a platform for future growth and create long-term shareholder value. We look forward to delivering on this important strategic priority."
Research and development expenses were approximately $0.9 million for the third quarter of 2026, compared to approximately $2.2 million for the same period in 2025. The decrease was primarily attributable to lower clinical costs related to Berubicin following the completion of enrollment and patient treatments in its clinical trial, as well as lower TPI 287 manufacturing costs. These decreases were partially offset by increased personnel-related expenses. Future research and development expenses will depend on the timing and nature of any assets the Company in-licenses or acquires and the associated development activities.
General and administrative expenses were approximately $1.8 million for the third quarter of 2026, compared to approximately $1.1 million for the same period in 2025. The increase was primarily attributable to higher consulting expenses, mainly related to business development, and increased personnel-related expenses, partially offset by lower professional services expenses.
Net loss for the third quarter of 2026 was approximately $2.5 million, or $0.24 per basic and diluted share, compared to a net loss of approximately $3.2 million, or $5.76 per basic and diluted share, for the third quarter of 2025.
Cash and cash equivalents were approximately $17.2 million as of September 30, 2026, compared to approximately $7.2 million as of December 31, 2025. The increase primarily reflects net proceeds from the Company's previously announced $22.5 million private placement financing completed in May 2026. The Company believes that its cash resources, including the net proceeds from the May 2026 financing, are sufficient to fund its planned operations beyond the next twelve months.
CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies for serious diseases. With an experienced executive team and a focus on high-value therapeutic opportunities, the Company is working to build a differentiated portfolio of assets addressing significant unmet medical needs. CNS is committed to advancing novel treatments that have the potential to improve patient outcomes while creating long-term value for patients and shareholders.
For more information, please visit www.CNSPharma.com , and connect with the Company on X and LinkedIn .
Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding the Company's strategic transformation and pipeline development plans, the Company's ability to identify, acquire and advance new therapeutic assets, expectations regarding the Company's ability to create long-term shareholder value, and the timing related to the execution of the Company's strategy. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "projects," "intends," "potential," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risk that current discussions may not result in a definitive transaction, that any acquired or licensed asset may not achieve clinical or commercial success, that additional capital may be required to fund future operations or transactions, as well as market and other conditions and those discussed under Item 1A. "Risk Factors" in CNS's most recently filed Form 10-K filed with the SEC and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.